Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches
Abstract The coronavirus disease 2019 (COVID‐19) has presented unprecedented challenges to the generic drug development, including interruptions in bioequivalence (BE) studies. Per guidance published by the US Food and Drug Administration (FDA) during the COVID‐19 public health emergency, any protoc...
Saved in:
Main Authors: | Yuqing Gong (Author), Kairui Feng (Author), Peijue Zhang (Author), Jieon Lee (Author), Yuzhuo Pan (Author), Zhen Zhang (Author), Zhanglin Ni (Author), Tao Bai (Author), Miyoung Yoon (Author), Bing Li (Author), Carol Y. Kim (Author), Lanyan Fang (Author), Liang Zhao (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery
by: Miyoung Yoon, et al.
Published: (2023) -
Establishing the suitability of model‐integrated evidence to demonstrate bioequivalence for long‐acting injectable and implantable drug products: Summary of workshop
by: Yuqing Gong, et al.
Published: (2023) -
Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies
by: Coralie Tardivon, et al.
Published: (2023) -
Critical Remarks on Reference-Scaled Average Bioequivalence
by: Helmut Schütz, et al.
Published: (2022) -
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview
by: Andrew Babiskin, et al.
Published: (2023)